HIV & రెట్రో వైరస్ జర్నల్ అందరికి ప్రవేశం

నైరూప్య

Three Months of Rifapentine Plus Isoniazid to Prevent Human Immuno Deficiency Virus Related Tuberculosis

Gudisa Bereda

Latent tuberculosis infection is delineated by an insistent immune reaction to Mycobacterium. tuberculosis antigens without confirmation of active infirmity. Subsequent weekly rifapentine and isoniazid are effective in the continuation phase of tuberculosis treatment in patients with a less bacillary refrain. Tuberculosis preventive treatment has dual considerable intentions: 1) defend people who are already infected with the tuberculosis bacterium from falling sick with active tuberculosis malady, and 2) ammunition people who are uninfected but at peril of tuberculosis liability from getting exposed in the first locale. The new regimen combines isoniazid and rifapentine and is bestowed in 12 once-weekly doses using directly observed therapy. A fixed-dose combination of rifapentine and isoniazid (300 mg/300 mg) that facilitates downhill administration of the 3-month Tuberculosis preventive treatment regimen of isoniazid and rifapentine in persons aged 13 years and above. The shorter duration of treatment with isoniazid and rifapentine and the greater rates of treatment completion make it more costeffective in the long-term.